Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Heart Failure with Preserved Ejection Fraction
CTR20171294Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF), chronic heart failure (CHF), sponsored by Boehringer Ingelheim. Started Dec 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on CTR20171294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171294.